ArticleActa Cardiologica Sinica2026
The Mechanism of KLF4-Mediated NF-κB/NLRP3 Pathway Regulating Arteriovenous Fistula Dysfunction.
Article in Acta Cardiologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- KLF4 in Parkinson's Disease: Decoding the Molecular Puzzle of Neuroinflammation, Oxidative Stress, and Emerging Therapies.Current medical science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Arteriovenous fistula (AVF) is the lifeline of maintenance hemodialysis (MHD), and AVF dysfunction is a major burden for MHD patients. It is important to modulate the vascular inflammatory response in pathological settings to protect endothelial proliferation and reduce AVF dysfunction. Krüppel-like factor 4 (KLF4) plays a key role in regulating the vascular endothelium in vascular homeostasis. In this study, we investigated the role of KLF4 in regulating the inflammatory pathway in vascular endothelial cells and its effect on biological behavior. Methods: An lipopolysaccharide (LPS)-induced inflammatory injury human umbilical vein endothelial cell (HUVEC) model was established, and cell morphology changes were observed microscopically. The overexpression or knockdown efficiency of KLF4 was verified by reverse transcription quantitative polymerase chain reaction (RT-qPCR), and the migration, proliferation, interleukin-6 and high sensitivity C-reactive protein expression levels of HUVECs were detected by Transwell assay, Cell Counting Kit-8 assay, and enzyme-linked immunosorbent assay, respectively. The expression levels of nuclear factor kappa-B (NF-κB) and nod-like receptor family pyrin domain containing 3 (NLRP3) were detected by RT-qPCR and Western blot. In addition, rescue experiments were performed by interfering with the NF-κB pathway to observe changes in experimental phenomena. Results: Compared with conventional culture, morphological changes, proliferation and mobility of continuous LPS-induced HUVECs significantly increased, along with significantly increased levels of NF-κB, NLRP3 and inflammatory factors. The overexpression of KLF4 resulted in the inhibition of NF-κB, NLRP3 and inflammatory factors, while cell proliferation and migration were significantly reduced. In comparison, knockdown of KLF4 produced opposite effects. When combined with NF-κB inhibitors, the effect of knockdown KLF4 was reversed. Conclusions: KLF4 protects endothelial cell proliferation by modulating the vascular inflammatory response, and is a potential target for reducing AVF dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.